Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38243170)

  • 1. Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
    Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
    Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer.
    Chen X; Hao Y; Liu Y; Zhong S; You Y; Ao K; Chong T; Luo X; Yin M; Ye M; He H; Lu A; Chen J; Li X; Zhang J; Guo X
    Adv Sci (Weinh); 2023 Nov; 10(32):e2302705. PubMed ID: 37818745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
    Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
    Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodelin, a N-acetyltransferase 10 (NAT10) inhibitor, alters mitochondrial lipid metabolism in cancer cells.
    Dalhat MH; Mohammed MRS; Ahmad A; Khan MI; Choudhry H
    J Cell Biochem; 2021 Dec; 122(12):1936-1945. PubMed ID: 34605570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodelin, an inhibitor of NAT10, could suppress hypoxia-induced or constitutional expression of HIFs in cells.
    Wu Y; Cao Y; Liu H; Yao M; Ma N; Zhang B
    Mol Cell Biochem; 2020 Sep; 472(1-2):19-31. PubMed ID: 32529496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of
    Ma N; Liu H; Wu Y; Yao M; Zhang B
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression.
    Deng M; Zhang L; Zheng W; Chen J; Du N; Li M; Chen W; Huang Y; Zeng N; Song Y; Chen Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):9. PubMed ID: 36609449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
    Tseng YJ; Lee CH; Chen WY; Yang JL; Tzeng HT
    J Invest Dermatol; 2021 Nov; 141(11):2690-2698.e6. PubMed ID: 34000287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetyltransferase NAT10 regulates the Wnt/β-catenin signaling pathway to promote colorectal cancer progression via ac
    Jin C; Wang T; Zhang D; Yang P; Zhang C; Peng W; Jin K; Wang L; Zhou J; Peng C; Tan Y; Ji J; Chen Z; Sun Q; Yang S; Tang J; Feng Y; Sun Y
    J Exp Clin Cancer Res; 2022 Dec; 41(1):345. PubMed ID: 36522719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights of human N-acetyltransferase 10 and identification of its potential novel inhibitors.
    Dalhat MH; Altayb HN; Khan MI; Choudhry H
    Sci Rep; 2021 Mar; 11(1):6051. PubMed ID: 33723305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.